Table 4.
Associations between polymorphic genotypes of high-mobility group box 1 (HMGB1) (rs1360485) and clinicopathologic characteristics of lung cancer with epidermal growth factor receptor (EGFR) mutations.
| Variable | EGFR mutation (N=169) | EGFR mutation with non-smoking (N=109) | EGFR mutation with smoking (N=60) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| TT (N=94) | TC+CC (N=75) | p value | TT (N=60) | TC+CC (N=49) | p value | TT (N=34) | TC+CC (N=26) | p value | |
| Stage | |||||||||
| I+II | 30 (31.9%) | 17 (22.7%) | p=0.182 | 20 (33.3%) | 12 (24.5%) | p=0.313 | 10 (29.4%) | 5 (19.2%) | p=0.367 |
| III+IV | 64 (68.1%) | 58 (77.3%) | 40 (66.7%) | 37 (75.5%) | 24 (70.6%) | 21 (80.8%) | |||
| Tumor T status | |||||||||
| T1+T2 | 62 (66.0%) | 46 (61.3%) | p=0.534 | 40 (66.7%) | 33 (67.3%) | p=0.940 | 22 (64.7%) | 13 (50.0%) | p=0.252 |
| T3+T4 | 32 (34.0%) | 29 (38.7%) | 20 (33.3%) | 16 (32.7%) | 12 (35.3%) | 13 (50.0%) | |||
| Lymph node status | |||||||||
| Negative | 34 (36.2%) | 20 (26.7%) | p=0.188 | 24 (40.0%) | 14 (28.6%) | p=0.213 | 10 (29.4%) | 6 (23.1%) | p=0.582 |
| Positive | 60 (63.8%) | 55 (73.3%) | 36 (60.0%) | 35 (71.4%) | 24 (70.6%) | 20 (76.9%) | |||
| Distant metastasis | |||||||||
| Negative | 47 (50.0%) | 33 (44.0%) | p=0.438 | 32 (53.3%) | 22 (44.9%) | p=0.381 | 15 (44.1%) | 11 (42.3%) | p=0.889 |
| Positive | 47 (50.0%) | 42 (56.0%) | 28 (46.7%) | 27 (55.1%) | 19 (55.9%) | 15 (57.7%) | |||
| Cell differentiation | |||||||||
| Well + Moderately | 92 (97.9%) | 67 (89.3%) | p=0.019*,a | 59 (98.3%) | 47 (95.9%) | p=0.443 | 33 (97.1%) | 20 (76.9%) | p=0.016*,b |
| Poorly | 2 (2.1%) | 8 (10.7%) | 1 (1.7%) | 2 (4.1%) | 1 (2.9%) | 6 (23.1%) | |||
* p value of <0.05 as statistically significant.
a Odds ratio (OR) (95% confidence interval (CI)) : 5.493 (1.130~26.696); b OR (95% CI): 9.900 (1.109~88.339).